CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC

La tecnología CRISPR-Cas fué descubierta por primera vez en S. pyogenes y corresponde a un sistema de defensa que poseen las bacterias contra los fagos y plásmidos; recientes investigaciones apuntan diferentes miras y alcances que posee esta herramienta en materia de edición génica. Sumado a esto, e...

Full description

Autores:
Quintero Pineda, Paula Daniela
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2021
Institución:
Colegio Mayor de Cundinamarca
Repositorio:
Repositorio Colegio Mayor de Cundinamarca
Idioma:
spa
OAI Identifier:
oai:repositorio.unicolmayor.edu.co:unicolmayor/6890
Acceso en línea:
https://repositorio.unicolmayor.edu.co/handle/unicolmayor/6890
Palabra clave:
CRISPR-Cas
Terapia viral oncolítica
Leucemia mieloide crónica
Adenovirus
Rights
closedAccess
License
Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
id UCOLMAYOR2_fbabbdffb6b7ea7fa317aa59b57ca8ab
oai_identifier_str oai:repositorio.unicolmayor.edu.co:unicolmayor/6890
network_acronym_str UCOLMAYOR2
network_name_str Repositorio Colegio Mayor de Cundinamarca
repository_id_str
dc.title.spa.fl_str_mv CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
title CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
spellingShingle CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
CRISPR-Cas
Terapia viral oncolítica
Leucemia mieloide crónica
Adenovirus
title_short CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
title_full CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
title_fullStr CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
title_full_unstemmed CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
title_sort CRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMC
dc.creator.fl_str_mv Quintero Pineda, Paula Daniela
dc.contributor.advisor.none.fl_str_mv Lòpez Lopez, Yalile Ibeth
dc.contributor.author.none.fl_str_mv Quintero Pineda, Paula Daniela
dc.contributor.corporatename.spa.fl_str_mv Universidad Colegio Mayor de Cundinamarca
dc.subject.proposal.spa.fl_str_mv CRISPR-Cas
Terapia viral oncolítica
Leucemia mieloide crónica
Adenovirus
topic CRISPR-Cas
Terapia viral oncolítica
Leucemia mieloide crónica
Adenovirus
description La tecnología CRISPR-Cas fué descubierta por primera vez en S. pyogenes y corresponde a un sistema de defensa que poseen las bacterias contra los fagos y plásmidos; recientes investigaciones apuntan diferentes miras y alcances que posee esta herramienta en materia de edición génica. Sumado a esto, en revisiones actuales se ha demostrado que la terapia viral oncolítica juega cada vez más un rol importante en la resolución tanto de tumores sólidos como de malignidades hematológicas como lo es la leucemia mieloide crónica (LMC). Es por ello, que esta revisión busca definir como alternativa terapéutica a los casos de frecuente recaída, la implementación de un modelo de Adenovirus genéticamente modificado por la tecnología CRISPR-Cas como posible alternativa terapéutica para la resolución de la LMC dentro del marco del análisis documental.
publishDate 2021
dc.date.issued.none.fl_str_mv 2021-10
dc.date.accessioned.none.fl_str_mv 2024-05-21T16:16:41Z
dc.date.available.none.fl_str_mv 2024-05-21T16:16:41Z
dc.type.spa.fl_str_mv Trabajo de grado - Pregrado
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.coarversion.spa.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/TP
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_7a1f
status_str publishedVersion
dc.identifier.uri.none.fl_str_mv https://repositorio.unicolmayor.edu.co/handle/unicolmayor/6890
url https://repositorio.unicolmayor.edu.co/handle/unicolmayor/6890
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv Pettersson U. Structural and Nonstructural Adenovirus Proteins.SpringerLink. [Internet].1984. [citado 4 sep 2020]. Available in: https://link.springer.com/chapter/10.1007/978-1-4684-7935-5_6
O'Dell T, Kandel E, & Grant S. Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature. [Internet]. 1991. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/353558a0
Vergara C, Martínez C. Las moléculas de adhesión y la respuesta inmune. Revista biomédica. [Internet].1994. [citado 4 sep 2020]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/2101-Texto%20del%20manuscrito%20co mpleto%20(cuadros%20y%20figuras%20insertos)-7677-1-10-20130829.pdf 4.
Traycoff C, Srour E, Dutt P, Cornetta F. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors. Nature. [Internet]. 1997. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/2400529#author-information
Peltola1 M, Kytta¨la¨A Heinonen O , Rapola J, Paunio T, Revah F. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Nature. [Internet].1998. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/3300740.pdf
Boyes J, Byfield p, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. [Internet].1998. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/25166
Gonzalez R, Vereecque R, Wickham T, Vanrumbeke M, Kovesdi I, Bauters F, et al. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Nature. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/3300836
Waller C, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Annals of hematology. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://link.springer.com/article/10.1007/s002770050527
Marini F, Yu Q,Wickham T, Kovesdi I,Andreeff M. Adenovirus as a gene therapy vector for hematopoietic cells. Nature. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/7700174
Flores J. Leucemia mieloide crónica. Interferón vs transplante de médula ósea. Oncohematología. [Internet]. 2000. [citado 4 sep 2020]. Disponible en: http://www.anmm.org.mx/bgmm/1864_2007/2000-136-SUP2-31-34.pdf
Morceau F, Dupont C, Palissot V, Borde-Chiché P, Trentesaux C, Dicato M, Diederich M. GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the γ-globin mRNA. Nature. [Internet].2000. [citado 12 sep 2020]. Available in: https://www.nature.com/articles/2401890
Cheshenko N, Krougliak N, Eisensmith R, Krougliak V. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Nature. [Internet].2001. [citado 6 sep 2020]. Available in: https://www.nature.com/articles/3301459#author-information
Bernaola G, Luque W. FISIOPATOLOGÍA DE LAS INFECCIONES POR ADENOVIRUS. [Internet] 2002 [citado 20 Abr 2020]. Available in: https://sisbib.unmsm.edu.pe/bvrevistas/paediatrica/v04_n2/fisiopatolog%C3%ADa.htm
Rosenfeld C, CheeverM, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Nature. [Internet]. 2003. [cited 20 Abr 2021]. Avalable in: https://www.nature.com/articles/2402988
Fernandez F. Estudio secuencial y cuantitativo del quimerismo hemopoyético en pacientes sometidos a un trasplante alogénico de progenitores hemopoyéticos con depleción linfoide T o con acondicionamiento sub-mieloablativo. TDX. [Internet] 2005 [citado 20 Abr 2021]. Disponible en: https://www.tdx.cat/handle/10803/2170#page=1
Zibert A, Thomassen A, Müller L, Nguyen L, Glouchkova L, Fraefel C, et al. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia. Nature. [Internet]. 2005. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/3302577#author-information
Martínez F, Orozco j, Fausto A, Villegas C. Biología molecular de los vectores adenovirales. Cirugía y Cirujanos [Internet]. 2006;74(6):483-493. [citado 6 sep 2020]. Disponible en: https://www.redalyc.org/pdf/662/66274613.pdf
Massarelli E. KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC. Nature. [Internet]. 2007. [citado 6 sep 2020]. Available in: https://www.nature.com/articles/ncponc0893
Zhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biology and Therapy. [Internet]. 2007. [citado 6 sep 2020]. Available in: https://www.tandfonline.com/doi/abs/10.4161/cbt.6.11.4831 20.
Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Nature. [Internet]. 2007. [Citado 09 jul 2021]. Available in: https://www.nature.com/articles/2405034#author-information
García J. FACTORES PRONÓSTICO EN LEUCEMIA MIELOIDE CRÓNICA FILADELFIA POSITIVA EN PACIENTES TRATADOS CON INHIBIDORES DE LA TIROSINCINASA [Internet] 2008 [citado 22 mar 2020]. Disponible en: https://hera.ugr.es/tesisugr/17647873.pdf
Salazar M. Técnicas para la detección de apoptosis y senescencia celular in vitro y su importancia en biotecnología de la salud. Revista colombiana de biotecnología. [Internet]. 2009. [citado 09 jul 2021]. Disponible en: https://revistas.unal.edu.co/index.php/biotecnologia/article/view/11762
Izarzugaza I, Martinez R, Audícana C, Larrañaga N, Hernandez E, Tobalina C, et al. EL CANCER EN EL PAIS VASCO. Vitoria-Gasteiz. [Internet]. 2010 [cited 4 sep 2020]. Disponible en: https://www.osakidetza.euskadi.eus/contenidos/informacion/estado_salud/es_5463/adjuntos/canc er.pdf
De Luca P, Zalazar F, Moiola C, Gueron G, Cotignola J, Vazquez E. RESÚMENES DE LAS COMUNICACIONES. Medicina (Buenos Aires). [Internet]. 2010 [cited 4 sep 2020]. Disponible en: https://eds-a-ebscohost-com.ezproxy.javeriana.edu.co/eds/pdfviewer/pdfviewer?vid=2&sid=fe44 0518-066c-4197-92de-d0f383add989%40sessionmgr4008
Poláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T. Expression patterns of microRNAs associated with CML phases and their disease related targets. Springer Link. [Internet].2013. [cited 11 sep 2020]. Available in: https://link.springer.com/article/10.1186/1476-4598-10-41#Abs1
Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to Biologics: Mechanisms, Prediction and Reduction. SpringerLink. [Internet]. 2012 [cited 4 sep 2020]. Available in: https://link.springer.com/article/10.1007/s00005-012-0189-7
Xu C, Fu H, Gao L, Wang L,Wang W, Li J. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Nature [Internet]. 2012 [cited 4 sep 2020]. Available in: https://www.nature.com/articles/onc2012557#author-information
Velásquez J, Fonseca D, Jacal M, Sánchez M, Sánchez D, Guerrero S. Diagnóstico citogenético y seguimiento molecular en la leucemia mieloide crónica. Esp Méd Quir. [Internet].2013. [citado 11 sep 2020].disponible en: https://www.medigraphic.com/pdfs/quirurgicas/rmq-2013/rmq133o.pdf
Yang Y, Xiao F, Lu Z, Li Z, Zuo H, Zhang Q, et al. Development of a novel adenovirus–alphavirus hybrid vector with RNA replicon features for malignant hematopoietic cell transduction. Nature. [Internet]. 2013. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/cgt201337
Mellier G, Liu D, Bellot G, Holme A, Pervaiz S. Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27. Nature. [Internet].2013. [cited 11 sep 2020]. Available in: https://www.nature.com/articles/cddis2013413
Organización mundial de la salud. Perfiles oncológicos de los países. OMS. [Internet] 2014 [citado 20 Abr 2020].Disponible en: https://www.who.int/cancer/country-profiles/col_es.pdf?ua=1
Nature. Genome editing for all. [Internet] 2014 [citado 20 Abr 2020]. Available in: https://www.nature.com/articles/nbt.2879
Yoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR–Cas platform. Nature. [Internet]. 2014 [cited 20 mar 2020]. Available in: https://www.nature.com/articles/ncomms5240#Sec6
Boyiadzis M, Whiteside L. Information transfer by exosomes: A new frontier in hematologic malignancies. Sciencedirect [Internet]. 2015 [cited 20 mar 2020]. Available in: https://www.sciencedirect.com/science/article/abs/pii/S0268960X15000132?via%3Dihub
Parrish C, Scott B, Migneco G, Scott J, Steele P, Ilett E, et al. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Nature [Internet]. 2015. [cited 9 jul 2021]. Available in: https://www.nature.com/articles/leu201588#author-information
Li H, Hui H, Xu J, Yang H, Zhang X, Liu X, et al. Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells. SpringerLink [Internet]. 2015 [cited 20 mar 2020]. Available in: https://link.springer.com/article/10.1007/s00204-015-1552-3
Naka k, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, et al. Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nature [Internet]. 2015 [cited 20 mar 2020]. Available in: https://www.nature.com/articles/ncomms9039
Garcia M. GENERACIÓN DE UN ADENOVIRUS QUIMÉRICO AD5/52s PSEUDOTIPADO CON LA PROTEÍNA FIBER CORTA DEL Ad52 PARA SU CARACTERIZACIÓN IN VITRO E IN VIVO COMO VECTOR DE TERAPIA GÉNICA. [Internet]. 2015 [citado 19 sep 2020]. Disponible en: https://ddd.uab.cat/pub/tesis/2016/hdl_10803_370116/mgm1de1.pdf
Mojica F. “Sistemas CRISPR-Cas, una revolución biotecnológica con origen bacteriano”. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.youtube.com/watch?v=GOK6FkfmHdQ
Wu B, Ingersoll K, Rehder C, Wang S. Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual. Annals of hematology. [Internet]. 2016. [cited 9 jul 2021]. Available in: https://link.springer.com/article/10.1007/s00277-016-2707-x
Abyntek. INTRODUCCIÓN A LA TECNOLOGÍA CRISPR-CAS 9. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.abyntek.com/introduccion-a-la-tecnologia-crispr/
Gonzalez S. La donación de médula ósea, influenciada por su desconocimiento. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: http://tauja.ujaen.es/bitstream/10953.1/3712/1/TFG_Sergio_Gonzlez_Martnez.pdf
Laila Y. Bielski, Ana M. Orlandi, Hugo R. Boquete. Inhibidores de tirosina cinasa y disfunción tiroidea. ELSEVIER. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.elsevier.es/es-revista-revista-argentina-endocrinologia-metabolismo-185-articulo-in hibidores-tirosina-cinasa-disfuncion-tiroidea-S0326461016300511
Heinrich J, Donakonda S, Joachim V, Lennig P, Zhang Y, Schroeder M. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells. Oncotarget. [Internet]. 2016 [cited 18 mar 2020]. Available in: https://www.oncotarget.com/article/11905/
Lompardía SL, Díaz M, Papademetrio DL, Pibuel M, Álvarez E, Hajos SE. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. SpringerLink [Internet]. 2016 [cited 18 mar 2020]. Available in: https://link.springer.com/article/10.1007%2Fs10637-016-0397-9
Smirnova O. Radiogenic Leukemia Risk Assessment. [Internet]. 2016. [cited 09 jul 2021]. Available in: https://link.springer.com/chapter/10.1007/978-3-319-45761-1_8
Wan T. Cancer Cytogenetics: An Introduction. SpringerLink [Internet]. 2016 [cited 18 mar 2020]. Available in: https://link.springer.com/protocol/10.1007%2F978-1-4939-6703-2_1
Bengio L, Enrico R, Freitas A, Larripa J, Pavlovsky I, Riveros M, et al. Leucemia mieloide crónica. Sociedad argentina de hematología. [Internet]. 2017 [citado 18 mar 2020]. Disponible en: http://sah.org.ar/docs/2017/008-Leucemia%20Mieloide%20Cr%C3%B3nica.pdf
Organización mundial de la salud. Probióticos y prebióticos. [Internet]. 2017 [citado 18 mar 2020]. Disponible en: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-spanis h-2017.pdf
Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, et al. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Oncotarget [Internet]. 2017 [cited 18 mar 2020]. Available in: https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5b% 5d=15957&pubmed-linkout=1
Wan, Thomas S. Cancer cytogenetics methods and protocols. SpringerLink. [Internet]. 2017 [cited 18 mar 2020]. Available in: https://www.springer.com/gp/book/9781493967018
Liang X, Potter J, Kumar S, Ravinder N, Chesnut J. Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. Journal of biotechnology. [Internet]. 2017. [cited 09 jul 2021]. Available in: https://www.sciencedirect.com/science/article/pii/S016816561631611X?via%3Dihub
Boyiadzis M, Whiteside L. The emerging roles of tumor-derived exosomes in hematological malignancies. Nature. [Internet]. 2017. [cited 18 mar 2020]. Available in: https://www.nature.com/articles/leu201791
Bengio R, Enrico A, Moiraghi B. Leucemia mieloide crónica. HEMATOLOGÍA. [Internet]. 2017 [cited 18 mar 2020]. Disponible en: http://sah.org.ar/docs/203-230.4.SAH_GUIA2012_LeucemiaCronica.pdf
Li L, You L, Mao L, Jin S, Chen X, Qian W. Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro [Internet]. 2017 [Cited 18 mar 2020]. Available in: https://www.nature.com/articles/aps2017100#Abs1
LY303511.1 KR 1020160079864-A/4030: OPTIMAL SOYBEAN LOCI. NIH [Internet]. 2017 [citado 11 sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/LY303511
Bianchini M. Biología de la leucemia mieloide crónica. Hematología [Internet]. 2017 [citado 20 mar 2020]. Disponible en: http://www.sah.org.ar/revista/numeros/vol21/extra3/38-vol21-extra_noviembre.pdf 77
Whiteside L. The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. NIH. [Internet]. 2017 [citado 20 mar 2020]. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827821/
Sarmiento D, Ruiz A. EVENTOS ADVERSOS Y PROBLEMAS RELACIONADOS CON MEDICAMENTOS INTERFERONES REPORTADOS EN BOGOTÁ D.C. 2008 – 2017. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://repository.udca.edu.co/bitstream/11158/1003/1/TRABAJO%20DE%20GRADO%20INTE RFERONES.pdf
Guerrero R. Caracterización del potencial oncolítico del aislamiento rotaviral Wt1-5 en cultivos primarios de leucemia linfoblástica aguda de precursores B. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/1049605017.2018.pdf
Hu H, Miller S, Geurts M, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. [Internet]. 2018. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/nature26155#author-information
Palacio G, Ramirez G, Muskus C, Torres J, Aya C. Detección de mutaciones en el dominio tirosina quinasa de BCR-ABL1 en pacientes colombianos con leucemia mieloide crónica LMC, resistentes al imatinib. ELSEVIER [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://www.elsevier.es/es-revista-revista-colombiana-cancerologia-361-articulo-deteccion-mutac iones-el-dominio-tirosina-S0123901518300210
Teepen C, Curtis R, Dores G, Gonzalez A, Eibrink M, Kremer L. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000–2014. Nature. [Internet]. 2018. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/s41375-018-0149-2
American Cancer Society.Trasplante de células madre para la leucemia mieloide crónica. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://www.cancer.org/es/cancer/leucemia-mieloide-cronica/tratamiento/celulas-madre-de-la-me dula-osea.html
Pinheiro T, Feitosa M, Santos M, Saraiva R, Longatti S. DIAGNÓSTICO LABORATORIAL DA LEUCEMIA MIELOIDE CRÔNICA. Revista de Medicina e Saúde de Brasília [Internet] 2018 [acima mencionado 6 sep 2020]. Disponível em: https://eds-b-ebscohost-com.ezproxy.javeriana.edu.co/eds/pdfviewer/pdfviewer?vid=2&sid=c81d e0f6-c4e1-4334-97f7-94367b224e6e%40sessionmgr101
NIH. Radioterapia para tratar el cáncer. NIH. [Internet]. 2019 [cited 15 mar 2020]. Disponible en: https://www.cancer.gov/espanol/cancer/tratamiento/tipos/radioterapia
Ma L, Pak L, Ou J, Yu J, Louis P, Shan Y, et al. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. PNAS [Internet]. 2019 [cited 15 mar 2020]. Available in: https://www.pnas.org/content/116/21/10482
Túlich L. Exosomas como sistemas de delivery de drogas. UTEC. [Internet]. 2019. [citado 15 mar 2021]. Disponible en: https://www.utec.edu.pe/blog-de-carreras/bioingenieria/exosomas-como-sistemas-de-delivery-de -drogas#:~:text=Exosomas%20como%20sistema%20de%20administraci%C3%B3n%20terap% C3%A9utica%3A,objetivos%20espec%C3%ADficos%20a%20larga%20distancia.
Pickar A, Gerbach C. The next generation of CRISPR–Cas technologies and applications. Nature [Internet]. 2019. [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41580-019-0131-5
Hu Y, Joo H, Lee K, Kim H, Didier R, Yang Y, et al. Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas9. Nature. [Internet] 2019 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41598-018-36736-y
Abudoureyimu M, Lai Y, Tian C, Wang T, Wang R, Chu X. Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front Oncol. [Internet] 2019 [cited 15 mar 2020]. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857090/
Ross Cloney. Gene editing by CRISPR–Cas. Nature. [Internet] 2019 [cited 14 abri 2021]. Available in: https://media.nature.com/original/magazine-assets/d42859-019-00088-y/d42859-019-00088-y.pd f
Veiga A. Células Stem mesenquimales en el transplante alogénico de progenitores hematopoyéticos: análisis de la experiencia clínica de la unidad de producción celular del Complejo Asistencial Universitario de Salamanca. [Internet] 2020 [cited 14 abri 2021]. Disponible en: https://gredos.usal.es/bitstream/handle/10366/145442/Veiga%20Vaz%2c%20Alvaro.pdf?sequenc e=1&isAllowed=y
Steegmann J, Casado L, Catellano P, Gómez M, Jiménez A, Peréz M, et al. Manual para el control y el tratamiento de los apcientes con leucemia mieloide crónica. GEL-MC. [Internet]. 2020. [Citado 27 marr 2021]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/Manual-GELMC-2020-VDigital.pdf
Doudna J. The promise and challenge of therapeutic genome editing. Nature. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41586-020-1978-5
Matthew C. A Workflow for Knock-in Genome Editing: Simplified. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.youtube.com/watch?v=Bto_v5au8o4
McCarty N, Graham A, Studená L, Amaro R. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nature. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41467-020-15053-x#author-information
Bajaj J, Hamilton M, Shima Y, Chambers K, Spinler K, Nostrand E, Yee B, et al. An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. Nature. [Internet]. 2020. [cited 09 jul 2021]. Available in: nature.com/articles/s43018-020-0054-2
Wang Z, Liu W, Wang L, Gao P, Li Z, Wu J, et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Nature. [Internet]. 2020. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/s41392-020-0135-9#Sec23
Acyrthosiphon pisum clone LLO1 p300 mRNA, partial cds. NIH [Internet]. 2020 [citado 12 sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/MN734788.1 81. Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, et al. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light
dc.rights.spa.fl_str_mv Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/closedAccess
dc.rights.creativecommons.spa.fl_str_mv Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_14cb
rights_invalid_str_mv Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024
https://creativecommons.org/licenses/by-nc/4.0/
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv closedAccess
dc.format.extent.spa.fl_str_mv 82p.
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Universidad Colegio Mayor de Cundinamarca
dc.publisher.faculty.spa.fl_str_mv Facultad de Ciencias de la Salud
dc.publisher.place.spa.fl_str_mv Bogotá D.C
dc.publisher.program.spa.fl_str_mv Bacteriología y Laboratorio Clínico
institution Colegio Mayor de Cundinamarca
bitstream.url.fl_str_mv https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/5/license.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/1/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.docx%282%29.pdf
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/2/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.pptx
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/3/FORMATO%20CARTA%20DERECHOS%20DE%20AUTOR%20FIRMA%20DECANA%20IIP2021%20Quintero.docx.pdf
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/4/1.FORMATO%20DERECHOS%20DE%20AUTOR%20TG%202021_%20PAULA%20QUINTERO.pdf
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/6/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.docx%282%29.pdf.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/8/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.pptx.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/9/FORMATO%20CARTA%20DERECHOS%20DE%20AUTOR%20FIRMA%20DECANA%20IIP2021%20Quintero.docx.pdf.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/11/1.FORMATO%20DERECHOS%20DE%20AUTOR%20TG%202021_%20PAULA%20QUINTERO.pdf.txt
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/7/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.docx%282%29.pdf.jpg
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/10/FORMATO%20CARTA%20DERECHOS%20DE%20AUTOR%20FIRMA%20DECANA%20IIP2021%20Quintero.docx.pdf.jpg
https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/12/1.FORMATO%20DERECHOS%20DE%20AUTOR%20TG%202021_%20PAULA%20QUINTERO.pdf.jpg
bitstream.checksum.fl_str_mv 2f9959eaf5b71fae44bbf9ec84150c7a
e69dcb4c998def967857166f9275cc3c
e634aa2af7c6a9e38f82e85b114f2522
cf6825b69aa4f9191d63efbf03edd21e
2def5bcc70bccca00eba424c01e2a771
68a6d3b301f54aa01151b5f3d9aa1d54
0ace8c9ee7e4417d8b9d1e0ecd7e9e86
e40cf9f065de3de9c6ce0c1302f274e4
d4103deb83b0258e262965dab5aeecbd
86320fc50b5dcf81a56ff1eba79cfb2e
3b3d7fe251944022e0db3cc2c5ee141f
abd7cad4acb801bd911d74b476519a1f
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital Unicolmayor
repository.mail.fl_str_mv repositorio@unicolmayor.edu.co
_version_ 1812210018824486912
spelling Lòpez Lopez, Yalile Ibeth387f2daeb88ac0c8e67c65303d688811Quintero Pineda, Paula Daniela93336d57783ad539c821e218ee2d60cbUniversidad Colegio Mayor de Cundinamarca2024-05-21T16:16:41Z2024-05-21T16:16:41Z2021-10https://repositorio.unicolmayor.edu.co/handle/unicolmayor/6890La tecnología CRISPR-Cas fué descubierta por primera vez en S. pyogenes y corresponde a un sistema de defensa que poseen las bacterias contra los fagos y plásmidos; recientes investigaciones apuntan diferentes miras y alcances que posee esta herramienta en materia de edición génica. Sumado a esto, en revisiones actuales se ha demostrado que la terapia viral oncolítica juega cada vez más un rol importante en la resolución tanto de tumores sólidos como de malignidades hematológicas como lo es la leucemia mieloide crónica (LMC). Es por ello, que esta revisión busca definir como alternativa terapéutica a los casos de frecuente recaída, la implementación de un modelo de Adenovirus genéticamente modificado por la tecnología CRISPR-Cas como posible alternativa terapéutica para la resolución de la LMC dentro del marco del análisis documental.CRISPR-Cas technology was discovered for the first time in S. pyogenes and is a defense system that bacteria have against phages and plasmids; Recent research points to different perspectives and scope of this tool in terms of gene editing. In addition to this, current reviews have shown 10 that oncolytic viral therapy plays an increasingly important role in the resolution of both solid tumors and hematological malignancies such as chronic myeloid leukemia (CML). For this reason, this review seeks to define as a therapeutic alternative to cases of relapse frequency, the implementation of a genetically modified Adenovirus model by CRISPR-Cas technology as a possible therapeutic alternative for the resolution of CML within the framework of the documentary analysis.Tabla de contenido 1. Resumen. 8 Glosario 9 2. Introducción. 12 3. Antecedentes. 14 4. Objetivos. 21 5. Diseño metodológico. 22 6. Marco referencial 23 6.1.1 Beneficios de la tecnología CRISPR-Cas. 24 6.1.2 Tecnología CRISPR-Cas en el siglo de la edición génica. 24 6.2 Adenovirus serotipo 5/52s. 25 6.2.1 Ligandos asociados a la partícula viral. 25 6.2.2 Patogenicidad y su implementación como modelo de terapia viral oncolítica. 26 6.2.3 Beneficios y ventajas de la terapia viral oncolítica. 28 6.2.4 Secuencias Knockout objetivo. 29 6.2.5 Alternativas para reducir la inmunogenicidad contra el modelo viral. 30 6.2.6 Ventajas del modelo Ad5/52s como terapia viral oncolítica sobre las demás alternativas terapéuticas existentes. 31 6.2.7 Otros modelos de terapia viral oncolítica. 31 6.3 Leucemia mieloide crónica 32 6.3.1 Generalidades y mutaciones genéticas implicadas. 33 6.3.2 Ruta diagnóstica. 35 6.3.3 Tratamientos convencionales disponibles. 35 6.3.3.1 Inhibidores de tirosina kinasa (ITK). 36 6.3.3.2 Terapia con interferón. 37 6.3.3.3 Radioterapia. 39 6.3.3.4 Trasplante de médula ósea. 40 6.3.4 Seguimiento al tratamiento en pacientes con LMC. 42 6 6.3.5 Marcadores conocidos de las células madre de la LMC. 42 6.3.5.1 Objetivos terapéuticos. 43 6.3.5.2 Papel de la proteína de choque térmico Hsp27, ADAR1 y GATA-1 en la supervivencia y proliferación celular. 44 6.3.5.3 Características de las secuencias Knockin para escindir sobre Hsp27, GATA-1 y ADAR1. 45 6.3.5.4 Transferencia de información mediada por exosomas. 47 6.3.5.4.1 Ventajas del uso de exosomas. 48 7. Análisis de la información encontrada. 49 7.1 Compilación y contraste de las alternativas terapéuticas disponibles y el modelo viral descrito. 49 7.2 Knockout génico del vector viral: construcción de la herramienta CRISPR-Cas 50 7.3 Knockin del vector viral: construcción teórica de plásmidos recombinantes. 51 7.4 Modelado del genoma viral resultante de la edición génica por CRISPR-Cas9. 52 7.5 Importancia relativa de las revistas compiladas: clasificación por cuartiles. 53 7.6 Importancia mundial de las malignidades hematológicas en el desarrollo investigativo. 53 7.7 Avances científicos orientados a las malignidades hematológicas a lo largo de los años. 55 8. Conclusiones 55 9. Discusión. 60PregradoBacteriólogo(a) y Laboratorista Clínico82p.application/pdfspaUniversidad Colegio Mayor de CundinamarcaFacultad de Ciencias de la SaludBogotá D.CBacteriología y Laboratorio ClínicoDerechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2024https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)http://purl.org/coar/access_right/c_14cbCRISPR-Cas y su aplicación sobre un modelo de Adenovirus como alternativa terapéutica para la resolución de la LMCTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1fhttp://purl.org/coar/version/c_970fb48d4fbd8a85Textinfo:eu-repo/semantics/bachelorThesishttps://purl.org/redcol/resource_type/TPinfo:eu-repo/semantics/publishedVersionPettersson U. Structural and Nonstructural Adenovirus Proteins.SpringerLink. [Internet].1984. [citado 4 sep 2020]. Available in: https://link.springer.com/chapter/10.1007/978-1-4684-7935-5_6O'Dell T, Kandel E, & Grant S. Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature. [Internet]. 1991. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/353558a0Vergara C, Martínez C. Las moléculas de adhesión y la respuesta inmune. Revista biomédica. [Internet].1994. [citado 4 sep 2020]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/2101-Texto%20del%20manuscrito%20co mpleto%20(cuadros%20y%20figuras%20insertos)-7677-1-10-20130829.pdf 4.Traycoff C, Srour E, Dutt P, Cornetta F. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors. Nature. [Internet]. 1997. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/2400529#author-informationPeltola1 M, Kytta¨la¨A Heinonen O , Rapola J, Paunio T, Revah F. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Nature. [Internet].1998. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/3300740.pdfBoyes J, Byfield p, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. [Internet].1998. [citado 4 sep 2020]. Available in: https://www.nature.com/articles/25166Gonzalez R, Vereecque R, Wickham T, Vanrumbeke M, Kovesdi I, Bauters F, et al. Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Nature. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/3300836Waller C, Fetscher S, Lange W. Treatment-related chronic myelogenous leukemia. Annals of hematology. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://link.springer.com/article/10.1007/s002770050527Marini F, Yu Q,Wickham T, Kovesdi I,Andreeff M. Adenovirus as a gene therapy vector for hematopoietic cells. Nature. [Internet]. 1999. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/7700174Flores J. Leucemia mieloide crónica. Interferón vs transplante de médula ósea. Oncohematología. [Internet]. 2000. [citado 4 sep 2020]. Disponible en: http://www.anmm.org.mx/bgmm/1864_2007/2000-136-SUP2-31-34.pdfMorceau F, Dupont C, Palissot V, Borde-Chiché P, Trentesaux C, Dicato M, Diederich M. GTP-mediated differentiation of the human K562 cell line: transient overexpression of GATA-1 and stabilization of the γ-globin mRNA. Nature. [Internet].2000. [citado 12 sep 2020]. Available in: https://www.nature.com/articles/2401890Cheshenko N, Krougliak N, Eisensmith R, Krougliak V. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Nature. [Internet].2001. [citado 6 sep 2020]. Available in: https://www.nature.com/articles/3301459#author-informationBernaola G, Luque W. FISIOPATOLOGÍA DE LAS INFECCIONES POR ADENOVIRUS. [Internet] 2002 [citado 20 Abr 2020]. Available in: https://sisbib.unmsm.edu.pe/bvrevistas/paediatrica/v04_n2/fisiopatolog%C3%ADa.htmRosenfeld C, CheeverM, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Nature. [Internet]. 2003. [cited 20 Abr 2021]. Avalable in: https://www.nature.com/articles/2402988Fernandez F. Estudio secuencial y cuantitativo del quimerismo hemopoyético en pacientes sometidos a un trasplante alogénico de progenitores hemopoyéticos con depleción linfoide T o con acondicionamiento sub-mieloablativo. TDX. [Internet] 2005 [citado 20 Abr 2021]. Disponible en: https://www.tdx.cat/handle/10803/2170#page=1Zibert A, Thomassen A, Müller L, Nguyen L, Glouchkova L, Fraefel C, et al. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia. Nature. [Internet]. 2005. [Cited 09 jul 2021]. Available in: https://www.nature.com/articles/3302577#author-informationMartínez F, Orozco j, Fausto A, Villegas C. Biología molecular de los vectores adenovirales. Cirugía y Cirujanos [Internet]. 2006;74(6):483-493. [citado 6 sep 2020]. Disponible en: https://www.redalyc.org/pdf/662/66274613.pdfMassarelli E. KRAS mutation is a predictor of poor response to EGFR tyrosine kinase inhibitors in NSCLC. Nature. [Internet]. 2007. [citado 6 sep 2020]. Available in: https://www.nature.com/articles/ncponc0893Zhang W, Cai R, Luo J, Wang Y, Cui Q, Wei X, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biology and Therapy. [Internet]. 2007. [citado 6 sep 2020]. Available in: https://www.tandfonline.com/doi/abs/10.4161/cbt.6.11.4831 20.Qian W, Liu J, Tong Y, Yan S, Yang C, Yang M, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Nature. [Internet]. 2007. [Citado 09 jul 2021]. Available in: https://www.nature.com/articles/2405034#author-informationGarcía J. FACTORES PRONÓSTICO EN LEUCEMIA MIELOIDE CRÓNICA FILADELFIA POSITIVA EN PACIENTES TRATADOS CON INHIBIDORES DE LA TIROSINCINASA [Internet] 2008 [citado 22 mar 2020]. Disponible en: https://hera.ugr.es/tesisugr/17647873.pdfSalazar M. Técnicas para la detección de apoptosis y senescencia celular in vitro y su importancia en biotecnología de la salud. Revista colombiana de biotecnología. [Internet]. 2009. [citado 09 jul 2021]. Disponible en: https://revistas.unal.edu.co/index.php/biotecnologia/article/view/11762Izarzugaza I, Martinez R, Audícana C, Larrañaga N, Hernandez E, Tobalina C, et al. EL CANCER EN EL PAIS VASCO. Vitoria-Gasteiz. [Internet]. 2010 [cited 4 sep 2020]. Disponible en: https://www.osakidetza.euskadi.eus/contenidos/informacion/estado_salud/es_5463/adjuntos/canc er.pdfDe Luca P, Zalazar F, Moiola C, Gueron G, Cotignola J, Vazquez E. RESÚMENES DE LAS COMUNICACIONES. Medicina (Buenos Aires). [Internet]. 2010 [cited 4 sep 2020]. Disponible en: https://eds-a-ebscohost-com.ezproxy.javeriana.edu.co/eds/pdfviewer/pdfviewer?vid=2&sid=fe44 0518-066c-4197-92de-d0f383add989%40sessionmgr4008Poláková K, Lopotová T, Klamová H, Burda P, Trněný M, Stopka T. Expression patterns of microRNAs associated with CML phases and their disease related targets. Springer Link. [Internet].2013. [cited 11 sep 2020]. Available in: https://link.springer.com/article/10.1186/1476-4598-10-41#Abs1Sethu S, Govindappa K, Alhaidari M, Pirmohamed M, Park K, Sathish J. Immunogenicity to Biologics: Mechanisms, Prediction and Reduction. SpringerLink. [Internet]. 2012 [cited 4 sep 2020]. Available in: https://link.springer.com/article/10.1007/s00005-012-0189-7Xu C, Fu H, Gao L, Wang L,Wang W, Li J. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Nature [Internet]. 2012 [cited 4 sep 2020]. Available in: https://www.nature.com/articles/onc2012557#author-informationVelásquez J, Fonseca D, Jacal M, Sánchez M, Sánchez D, Guerrero S. Diagnóstico citogenético y seguimiento molecular en la leucemia mieloide crónica. Esp Méd Quir. [Internet].2013. [citado 11 sep 2020].disponible en: https://www.medigraphic.com/pdfs/quirurgicas/rmq-2013/rmq133o.pdfYang Y, Xiao F, Lu Z, Li Z, Zuo H, Zhang Q, et al. Development of a novel adenovirus–alphavirus hybrid vector with RNA replicon features for malignant hematopoietic cell transduction. Nature. [Internet]. 2013. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/cgt201337Mellier G, Liu D, Bellot G, Holme A, Pervaiz S. Small molecule sensitization to TRAIL is mediated via nuclear localization, phosphorylation and inhibition of chaperone activity of Hsp27. Nature. [Internet].2013. [cited 11 sep 2020]. Available in: https://www.nature.com/articles/cddis2013413Organización mundial de la salud. Perfiles oncológicos de los países. OMS. [Internet] 2014 [citado 20 Abr 2020].Disponible en: https://www.who.int/cancer/country-profiles/col_es.pdf?ua=1Nature. Genome editing for all. [Internet] 2014 [citado 20 Abr 2020]. Available in: https://www.nature.com/articles/nbt.2879Yoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR–Cas platform. Nature. [Internet]. 2014 [cited 20 mar 2020]. Available in: https://www.nature.com/articles/ncomms5240#Sec6Boyiadzis M, Whiteside L. Information transfer by exosomes: A new frontier in hematologic malignancies. Sciencedirect [Internet]. 2015 [cited 20 mar 2020]. Available in: https://www.sciencedirect.com/science/article/abs/pii/S0268960X15000132?via%3DihubParrish C, Scott B, Migneco G, Scott J, Steele P, Ilett E, et al. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Nature [Internet]. 2015. [cited 9 jul 2021]. Available in: https://www.nature.com/articles/leu201588#author-informationLi H, Hui H, Xu J, Yang H, Zhang X, Liu X, et al. Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells. SpringerLink [Internet]. 2015 [cited 20 mar 2020]. Available in: https://link.springer.com/article/10.1007/s00204-015-1552-3Naka k, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, et al. Dipeptide species regulate p38MAPK–Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nature [Internet]. 2015 [cited 20 mar 2020]. Available in: https://www.nature.com/articles/ncomms9039Garcia M. GENERACIÓN DE UN ADENOVIRUS QUIMÉRICO AD5/52s PSEUDOTIPADO CON LA PROTEÍNA FIBER CORTA DEL Ad52 PARA SU CARACTERIZACIÓN IN VITRO E IN VIVO COMO VECTOR DE TERAPIA GÉNICA. [Internet]. 2015 [citado 19 sep 2020]. Disponible en: https://ddd.uab.cat/pub/tesis/2016/hdl_10803_370116/mgm1de1.pdfMojica F. “Sistemas CRISPR-Cas, una revolución biotecnológica con origen bacteriano”. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.youtube.com/watch?v=GOK6FkfmHdQWu B, Ingersoll K, Rehder C, Wang S. Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual. Annals of hematology. [Internet]. 2016. [cited 9 jul 2021]. Available in: https://link.springer.com/article/10.1007/s00277-016-2707-xAbyntek. INTRODUCCIÓN A LA TECNOLOGÍA CRISPR-CAS 9. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.abyntek.com/introduccion-a-la-tecnologia-crispr/Gonzalez S. La donación de médula ósea, influenciada por su desconocimiento. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: http://tauja.ujaen.es/bitstream/10953.1/3712/1/TFG_Sergio_Gonzlez_Martnez.pdfLaila Y. Bielski, Ana M. Orlandi, Hugo R. Boquete. Inhibidores de tirosina cinasa y disfunción tiroidea. ELSEVIER. [Internet]. 2016 [cited 18 mar 2020]. Disponible en: https://www.elsevier.es/es-revista-revista-argentina-endocrinologia-metabolismo-185-articulo-in hibidores-tirosina-cinasa-disfuncion-tiroidea-S0326461016300511Heinrich J, Donakonda S, Joachim V, Lennig P, Zhang Y, Schroeder M. New HSP27 inhibitors efficiently suppress drug resistance development in cancer cells. Oncotarget. [Internet]. 2016 [cited 18 mar 2020]. Available in: https://www.oncotarget.com/article/11905/Lompardía SL, Díaz M, Papademetrio DL, Pibuel M, Álvarez E, Hajos SE. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines. SpringerLink [Internet]. 2016 [cited 18 mar 2020]. Available in: https://link.springer.com/article/10.1007%2Fs10637-016-0397-9Smirnova O. Radiogenic Leukemia Risk Assessment. [Internet]. 2016. [cited 09 jul 2021]. Available in: https://link.springer.com/chapter/10.1007/978-3-319-45761-1_8Wan T. Cancer Cytogenetics: An Introduction. SpringerLink [Internet]. 2016 [cited 18 mar 2020]. Available in: https://link.springer.com/protocol/10.1007%2F978-1-4939-6703-2_1Bengio L, Enrico R, Freitas A, Larripa J, Pavlovsky I, Riveros M, et al. Leucemia mieloide crónica. Sociedad argentina de hematología. [Internet]. 2017 [citado 18 mar 2020]. Disponible en: http://sah.org.ar/docs/2017/008-Leucemia%20Mieloide%20Cr%C3%B3nica.pdfOrganización mundial de la salud. Probióticos y prebióticos. [Internet]. 2017 [citado 18 mar 2020]. Disponible en: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-spanis h-2017.pdfChen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, et al. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Oncotarget [Internet]. 2017 [cited 18 mar 2020]. Available in: https://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5b% 5d=15957&pubmed-linkout=1Wan, Thomas S. Cancer cytogenetics methods and protocols. SpringerLink. [Internet]. 2017 [cited 18 mar 2020]. Available in: https://www.springer.com/gp/book/9781493967018Liang X, Potter J, Kumar S, Ravinder N, Chesnut J. Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA. Journal of biotechnology. [Internet]. 2017. [cited 09 jul 2021]. Available in: https://www.sciencedirect.com/science/article/pii/S016816561631611X?via%3DihubBoyiadzis M, Whiteside L. The emerging roles of tumor-derived exosomes in hematological malignancies. Nature. [Internet]. 2017. [cited 18 mar 2020]. Available in: https://www.nature.com/articles/leu201791Bengio R, Enrico A, Moiraghi B. Leucemia mieloide crónica. HEMATOLOGÍA. [Internet]. 2017 [cited 18 mar 2020]. Disponible en: http://sah.org.ar/docs/203-230.4.SAH_GUIA2012_LeucemiaCronica.pdfLi L, You L, Mao L, Jin S, Chen X, Qian W. Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro [Internet]. 2017 [Cited 18 mar 2020]. Available in: https://www.nature.com/articles/aps2017100#Abs1LY303511.1 KR 1020160079864-A/4030: OPTIMAL SOYBEAN LOCI. NIH [Internet]. 2017 [citado 11 sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/LY303511Bianchini M. Biología de la leucemia mieloide crónica. Hematología [Internet]. 2017 [citado 20 mar 2020]. Disponible en: http://www.sah.org.ar/revista/numeros/vol21/extra3/38-vol21-extra_noviembre.pdf 77Whiteside L. The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. NIH. [Internet]. 2017 [citado 20 mar 2020]. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827821/Sarmiento D, Ruiz A. EVENTOS ADVERSOS Y PROBLEMAS RELACIONADOS CON MEDICAMENTOS INTERFERONES REPORTADOS EN BOGOTÁ D.C. 2008 – 2017. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://repository.udca.edu.co/bitstream/11158/1003/1/TRABAJO%20DE%20GRADO%20INTE RFERONES.pdfGuerrero R. Caracterización del potencial oncolítico del aislamiento rotaviral Wt1-5 en cultivos primarios de leucemia linfoblástica aguda de precursores B. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/1049605017.2018.pdfHu H, Miller S, Geurts M, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. [Internet]. 2018. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/nature26155#author-informationPalacio G, Ramirez G, Muskus C, Torres J, Aya C. Detección de mutaciones en el dominio tirosina quinasa de BCR-ABL1 en pacientes colombianos con leucemia mieloide crónica LMC, resistentes al imatinib. ELSEVIER [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://www.elsevier.es/es-revista-revista-colombiana-cancerologia-361-articulo-deteccion-mutac iones-el-dominio-tirosina-S0123901518300210Teepen C, Curtis R, Dores G, Gonzalez A, Eibrink M, Kremer L. Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000–2014. Nature. [Internet]. 2018. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/s41375-018-0149-2American Cancer Society.Trasplante de células madre para la leucemia mieloide crónica. [Internet]. 2018 [citado 19 sep 2020]. Disponible en: https://www.cancer.org/es/cancer/leucemia-mieloide-cronica/tratamiento/celulas-madre-de-la-me dula-osea.htmlPinheiro T, Feitosa M, Santos M, Saraiva R, Longatti S. DIAGNÓSTICO LABORATORIAL DA LEUCEMIA MIELOIDE CRÔNICA. Revista de Medicina e Saúde de Brasília [Internet] 2018 [acima mencionado 6 sep 2020]. Disponível em: https://eds-b-ebscohost-com.ezproxy.javeriana.edu.co/eds/pdfviewer/pdfviewer?vid=2&sid=c81d e0f6-c4e1-4334-97f7-94367b224e6e%40sessionmgr101NIH. Radioterapia para tratar el cáncer. NIH. [Internet]. 2019 [cited 15 mar 2020]. Disponible en: https://www.cancer.gov/espanol/cancer/tratamiento/tipos/radioterapiaMa L, Pak L, Ou J, Yu J, Louis P, Shan Y, et al. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. PNAS [Internet]. 2019 [cited 15 mar 2020]. Available in: https://www.pnas.org/content/116/21/10482Túlich L. Exosomas como sistemas de delivery de drogas. UTEC. [Internet]. 2019. [citado 15 mar 2021]. Disponible en: https://www.utec.edu.pe/blog-de-carreras/bioingenieria/exosomas-como-sistemas-de-delivery-de -drogas#:~:text=Exosomas%20como%20sistema%20de%20administraci%C3%B3n%20terap% C3%A9utica%3A,objetivos%20espec%C3%ADficos%20a%20larga%20distancia.Pickar A, Gerbach C. The next generation of CRISPR–Cas technologies and applications. Nature [Internet]. 2019. [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41580-019-0131-5Hu Y, Joo H, Lee K, Kim H, Didier R, Yang Y, et al. Streamlined procedure for gene knockouts using all-in-one adenoviral CRISPR-Cas9. Nature. [Internet] 2019 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41598-018-36736-yAbudoureyimu M, Lai Y, Tian C, Wang T, Wang R, Chu X. Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front Oncol. [Internet] 2019 [cited 15 mar 2020]. Available in: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857090/Ross Cloney. Gene editing by CRISPR–Cas. Nature. [Internet] 2019 [cited 14 abri 2021]. Available in: https://media.nature.com/original/magazine-assets/d42859-019-00088-y/d42859-019-00088-y.pd fVeiga A. Células Stem mesenquimales en el transplante alogénico de progenitores hematopoyéticos: análisis de la experiencia clínica de la unidad de producción celular del Complejo Asistencial Universitario de Salamanca. [Internet] 2020 [cited 14 abri 2021]. Disponible en: https://gredos.usal.es/bitstream/handle/10366/145442/Veiga%20Vaz%2c%20Alvaro.pdf?sequenc e=1&isAllowed=ySteegmann J, Casado L, Catellano P, Gómez M, Jiménez A, Peréz M, et al. Manual para el control y el tratamiento de los apcientes con leucemia mieloide crónica. GEL-MC. [Internet]. 2020. [Citado 27 marr 2021]. Disponible en: file:///C:/Users/COMPAC%20PRESARIO/Downloads/Manual-GELMC-2020-VDigital.pdfDoudna J. The promise and challenge of therapeutic genome editing. Nature. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41586-020-1978-5Matthew C. A Workflow for Knock-in Genome Editing: Simplified. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.youtube.com/watch?v=Bto_v5au8o4McCarty N, Graham A, Studená L, Amaro R. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. Nature. [Internet] 2020 [cited 15 mar 2020]. Available in: https://www.nature.com/articles/s41467-020-15053-x#author-informationBajaj J, Hamilton M, Shima Y, Chambers K, Spinler K, Nostrand E, Yee B, et al. An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. Nature. [Internet]. 2020. [cited 09 jul 2021]. Available in: nature.com/articles/s43018-020-0054-2Wang Z, Liu W, Wang L, Gao P, Li Z, Wu J, et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Nature. [Internet]. 2020. [cited 09 jul 2021]. Available in: https://www.nature.com/articles/s41392-020-0135-9#Sec23Acyrthosiphon pisum clone LLO1 p300 mRNA, partial cds. NIH [Internet]. 2020 [citado 12 sep 2020]. Disponible en: https://www.ncbi.nlm.nih.gov/nuccore/MN734788.1 81. Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A, et al. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic lightCRISPR-CasTerapia viral oncolíticaLeucemia mieloide crónicaAdenovirusLICENSElicense.txtlicense.txttext/plain; charset=utf-814828https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/5/license.txt2f9959eaf5b71fae44bbf9ec84150c7aMD55open accessORIGINALCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.docx(2).pdfCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.docx(2).pdfapplication/pdf463500https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/1/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.docx%282%29.pdfe69dcb4c998def967857166f9275cc3cMD51open accessCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.pptxCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.pptxapplication/vnd.openxmlformats-officedocument.presentationml.presentation12635315https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/2/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.pptxe634aa2af7c6a9e38f82e85b114f2522MD52open accessFORMATO CARTA DERECHOS DE AUTOR FIRMA DECANA IIP2021 Quintero.docx.pdfFORMATO CARTA DERECHOS DE AUTOR FIRMA DECANA IIP2021 Quintero.docx.pdfapplication/pdf95884https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/3/FORMATO%20CARTA%20DERECHOS%20DE%20AUTOR%20FIRMA%20DECANA%20IIP2021%20Quintero.docx.pdfcf6825b69aa4f9191d63efbf03edd21eMD53metadata only access1.FORMATO DERECHOS DE AUTOR TG 2021_ PAULA QUINTERO.pdf1.FORMATO DERECHOS DE AUTOR TG 2021_ PAULA QUINTERO.pdfapplication/pdf206251https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/4/1.FORMATO%20DERECHOS%20DE%20AUTOR%20TG%202021_%20PAULA%20QUINTERO.pdf2def5bcc70bccca00eba424c01e2a771MD54metadata only accessTEXTCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.docx(2).pdf.txtCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.docx(2).pdf.txtExtracted texttext/plain167462https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/6/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.docx%282%29.pdf.txt68a6d3b301f54aa01151b5f3d9aa1d54MD56open accessCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.pptx.txtCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.pptx.txtExtracted texttext/plain41199https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/8/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.pptx.txt0ace8c9ee7e4417d8b9d1e0ecd7e9e86MD58open accessFORMATO CARTA DERECHOS DE AUTOR FIRMA DECANA IIP2021 Quintero.docx.pdf.txtFORMATO CARTA DERECHOS DE AUTOR FIRMA DECANA IIP2021 Quintero.docx.pdf.txtExtracted texttext/plain1058https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/9/FORMATO%20CARTA%20DERECHOS%20DE%20AUTOR%20FIRMA%20DECANA%20IIP2021%20Quintero.docx.pdf.txte40cf9f065de3de9c6ce0c1302f274e4MD59metadata only access1.FORMATO DERECHOS DE AUTOR TG 2021_ PAULA QUINTERO.pdf.txt1.FORMATO DERECHOS DE AUTOR TG 2021_ PAULA QUINTERO.pdf.txtExtracted texttext/plain2028https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/11/1.FORMATO%20DERECHOS%20DE%20AUTOR%20TG%202021_%20PAULA%20QUINTERO.pdf.txtd4103deb83b0258e262965dab5aeecbdMD511metadata only accessTHUMBNAILCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.docx(2).pdf.jpgCRISPR-Cas Y SU APLICACIÓN SOBRE UN MODELO DE ADENOVIRUS COMO ALTERNATIVA TERAPÉUTICA PARA LA RESOLUCIÓN DE LA LMC.docx(2).pdf.jpgGenerated Thumbnailimage/jpeg6580https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/7/CRISPR-Cas%20Y%20SU%20APLICACI%c3%93N%20SOBRE%20UN%20MODELO%20DE%20ADENOVIRUS%20COMO%20ALTERNATIVA%20TERAP%c3%89UTICA%20PARA%20LA%20RESOLUCI%c3%93N%20DE%20LA%20LMC.docx%282%29.pdf.jpg86320fc50b5dcf81a56ff1eba79cfb2eMD57open accessFORMATO CARTA DERECHOS DE AUTOR FIRMA DECANA IIP2021 Quintero.docx.pdf.jpgFORMATO CARTA DERECHOS DE AUTOR FIRMA DECANA IIP2021 Quintero.docx.pdf.jpgGenerated Thumbnailimage/jpeg9850https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/10/FORMATO%20CARTA%20DERECHOS%20DE%20AUTOR%20FIRMA%20DECANA%20IIP2021%20Quintero.docx.pdf.jpg3b3d7fe251944022e0db3cc2c5ee141fMD510metadata only access1.FORMATO DERECHOS DE AUTOR TG 2021_ PAULA QUINTERO.pdf.jpg1.FORMATO DERECHOS DE AUTOR TG 2021_ PAULA QUINTERO.pdf.jpgGenerated Thumbnailimage/jpeg11253https://repositorio.unicolmayor.edu.co/bitstream/unicolmayor/6890/12/1.FORMATO%20DERECHOS%20DE%20AUTOR%20TG%202021_%20PAULA%20QUINTERO.pdf.jpgabd7cad4acb801bd911d74b476519a1fMD512metadata only accessunicolmayor/6890oai:repositorio.unicolmayor.edu.co:unicolmayor/68902024-05-22 03:00:21.288An error occurred on the license name.|||https://creativecommons.org/licenses/by-nc/4.0/open accessBiblioteca Digital Unicolmayorrepositorio@unicolmayor.edu.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

Publicaciones similares